Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Austin Chen

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Respiratory Research|August 31, 2025
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosisMichael Poon, Kym Lorrain, Alexander Broadhead, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2014
Identification of the first potent, selective and bioavailable PPARα antagonistYalda Bravo, Christopher S Baccei, Alex Broadhead, et al.
Journal of Medicinal Chemistry|June 29, 2026
Discovery of <b>PIPE-791</b>, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory DisordersAustin Chen, Christopher Baccei, Jill Baccei, et al.
Molecular Medicine (Cambridge, Mass.)|June 13, 2015
A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In VivoDavorka Messmer, Kymmy Lorrain, Karin Stebbins, et al.
European Journal of Pharmacology|May 10, 2017
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonistKarin J Stebbins, Alex R Broadhead, Geraldine Cabrera, et al.
The Journal of Craniofacial Surgery|January 15, 2019
Reconstruction of Mohs Defects Located in the Head and NeckSabine A Egeler, Anna Rose Johnson, Ahmed M S Ibrahim, et al.
Cancer Research Communications|August 10, 2023
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing TumorsBrian J Francica, Anja Holtz, Justine Lopez, et al.
Science Advances|July 9, 2025
Biorhythms derived from consumer wearables predict postoperative complications in childrenRui Hua, Michela Carter, Megan K O'Brien, et al.
Digital Health|July 6, 2026
Rest-activity rhythmicity as digital biomarkers of postoperative recovery and complications in childrenMichela Carter, Rui Hua, Megan K O'Brien, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2011
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidinesAustin Chen, Renee Aspiotis, Louis-Charles Campeau, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Respiratory Research|August 31, 2025
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosisMichael Poon, Kym Lorrain, Alexander Broadhead, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2014
Identification of the first potent, selective and bioavailable PPARα antagonistYalda Bravo, Christopher S Baccei, Alex Broadhead, et al.
Journal of Medicinal Chemistry|June 29, 2026
Discovery of <b>PIPE-791</b>, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory DisordersAustin Chen, Christopher Baccei, Jill Baccei, et al.
Molecular Medicine (Cambridge, Mass.)|June 13, 2015
A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In VivoDavorka Messmer, Kymmy Lorrain, Karin Stebbins, et al.
European Journal of Pharmacology|May 10, 2017
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonistKarin J Stebbins, Alex R Broadhead, Geraldine Cabrera, et al.
The Journal of Craniofacial Surgery|January 15, 2019
Reconstruction of Mohs Defects Located in the Head and NeckSabine A Egeler, Anna Rose Johnson, Ahmed M S Ibrahim, et al.
Cancer Research Communications|August 10, 2023
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing TumorsBrian J Francica, Anja Holtz, Justine Lopez, et al.
Science Advances|July 9, 2025
Biorhythms derived from consumer wearables predict postoperative complications in childrenRui Hua, Michela Carter, Megan K O'Brien, et al.
Digital Health|July 6, 2026
Rest-activity rhythmicity as digital biomarkers of postoperative recovery and complications in childrenMichela Carter, Rui Hua, Megan K O'Brien, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2011
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidinesAustin Chen, Renee Aspiotis, Louis-Charles Campeau, et al.
Pageof 6